Disruptive technologies are one of many contributing factors to the changing regulatory intelligence industry. Learn more below from Vada Perkins, one of many expert presenters at the Q1 Productions 2nd Annual Life Science Regulatory Intelligence, Strategy & Execution Conference below.

 

Can you please describe your job title and what your position entails?

 

I am an Executive Director for Regulatory Policy & Intelligence/Head, Regulatory Intelligence for Bayer Pharmaceuticals and a former FDA Senior Advisor for Regulatory Science with global regulatory policy and intelligence expertise. My role involves the application of international data standards and technology to regulatory science and informatics/telematics initiatives and collaboration with national and international stakeholders to promote convergence in data interoperability and governance for regulatory optimization. The scope of my activities include Real-World Data/Real World Evidence (RWD/RWE), clinical, CMC data regulatory initiatives and the strategic application of emerging technologies (e.g. Artificial Intelligence, Machine Learning) and international data standards to support global regulatory harmonization and convergence.

 

Can you provide a summary of your presentation?

 

Advances in technology are contributing to a changing landscape within the pharmaceutical industry. Data and decision science offers opportunities to solve increasingly complex challenges in a data-driven manner. Advanced analytics, Machine Learning (ML) and Artificial Intelligence (AI) have the potential to afford business leaders the opportunity to apply quantitative techniques to concepts, such as decision and risk analysis, cost-benefit and effectiveness to better inform decision-making.

 

What are some key takeaways you hope attendees gain from the sessions?

 

I hope attendees learn how the application of innovative technologies such as AI, ML and advanced analytics can support regulatory intelligence in monitoring the regulatory landscape from a descriptive to more predictive and prescriptive model.

 

Why do you think regulatory intelligence teams should attend the conference?

 

Teams should attend because regulatory intelligence is a very dynamic and broad spectrum activity for more effective and efficient regulatory decision-making. Technology and innovation (e..g. PharmaTech, RegTech) can lend itself to a variety of regulatory intelligence business use cases to reduce administrative and regulatory burden and to focus intellectual capital and knowledge management on more critical organizational and regulatory priorities to maximize business value and return on investment.

 

Participate in an upcoming Regulatory Intelligence, Strategy & Execution Conference to learn more about the changing regulatory intelligence landscape.

 

Q1Web Admin is a Content Marketing Associate for Q1 Productions, where she is responsible for campaign planning, content development and executing marketing projects for the life sciences, pharmaceutical and food and beverage industries.